K-fold cross validation accuracy of different models. by Shayla Naznin (13014015)

Subjects:

Fig 5 - by Lingru Ruan (18995544)

Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

“…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC_{(tofacitinib, 0–∞)} and a 9.61-fold increase of colonic AUC_{(tofacitinib, 0–12h)}, compared with tofacitinib at a molar equivalent oral dose. …”

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Efficacy end points. by Youngmin Ko (3333819)

Subjects:

Effect sizes (if > 0.5) for the comparison of increasing load vs. decreasing for the iliocostalis muscle. by Christoph Anders (4068499)

Mutations in p38 MAP kinase components and the mucolipin ortholog CUP-5 suppress the decrease in abundance of RAB-7 in <i>madd-3</i> mutants. by Serena A. D’Souza (2635801)

Effect of seed priming on anti-oxidants and lipid peroxidation in pearl millet at 50 DAS. by N. K. Gupta (11211399)

Overexpression of TNFAIP9 remitted the renal inflammation caused by 5/6 Nx in C57 mice. by Ying Chen (9697)

Overexpression of TNFAIP9 counteracted the renal damage caused by 5/6 Nx in C57 mice. by Ying Chen (9697)

Blockade of kinin B₁R in the chronic disease phase decreased the clinical symptoms and neuroinflammation in the EAE model. by Rafael C. Dutra (205755)

VAMP2 decreases 5-HT uptake and SERT cell surface expression in HEK-293 MSR cells by reducing the delivery rate of the transporter to the plasma membrane. by Heidi Kaastrup Müller (570207)

Fibrosis markers. by Dwight D. Harris (14484648)

Supplementary Material for: Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (... by figshare admin karger (2628495)

Proline is toxic in cells unable to catabolize it. by Fitz Gerald S. Silao (9384713)

Immunoblotting for TGF-beta, alpha-actinin, MMP-13, and mTOR. by Dwight D. Harris (14484648)

Immunoblotting for JAK, STAT, and SMAD. by Dwight D. Harris (14484648)

Immunoblotting FOXO1 and insulin receptors. by Dwight D. Harris (14484648)

Cellular uptake of [¹⁴C]docosahexaenoic acid (DHA) by RBECs transfected with MFSD2A siRNA. by Takuro Iwao (14636741)

Immunoblotting for insulin sensitivity markers. by Dwight D. Harris (14484648)